Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

August 6, 2024

https://www.prnewswire.com/news-releases/elevation-oncology-announces-promising-initial-data-from-phase-1-clinical-trial-evaluating-eo-3021-in-patients-with-advanced-unresectable-or-metastatic-solid-tumors-likely-to-express-claudin-18-2–302215418.html

— 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer —
— EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia — 
— Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 —
— Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 —
— Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET —

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.